| | | |   | | | | By Ambar Castillo MacArthur Foundation “What we need to do now is ... understand: Why did [pharma] have this much power in the first place? And patents are the first place to look.” Read More | | By Lev Facher Hyacinth Empinado/STAT There's a push to swap out terms like "addict" or "substance abuse" in favor of language that recognizes addiction as a medical condition. Read More | | By John Michael O'Brien Adobe Stock The 340B Drug Discount Program is now a giant federal program. But it's impossible to tell where the money is going. That needs to change. Read More | | Sponsored Insight by Optum Clinicogenomics: How new, linked data is advancing life sciences research Clinicogenomics offers life sciences researchers a powerful new tool by linking genomic data to rich, longitudinal clinical information. The life science research community is only beginning to unlock its potential to better understand disease pathways, discover novel therapeutic targets, identify variation in disease onset and progression, and evaluate drug safety and efficacy. Read this white paper to get an in-depth look into this rapidly evolving field of research. | | By Allison DeAngelis Courtesy Stefan Simchowitz Tim Wright and D.A. Wallach have forged an unlikely alliance based on their shared interest in health care and investment. Read More | |
No comments